CHF5993 pMDI with HFA-152a

Phase 2

Chiesi Farmaceutici S.p.A.

CHF5993 pMDI with HFA-152a is one of 18 therapeutic programs targeting Asthma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

AsthmaRecruiting

AsthmaPhase 2

Recruiting

Competition

Competitive Landscape

1050 competitors in Asthma

#DrugCompanyPhaseTrials

Singulair

AstraZeneca

Preclinical

17 2

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

30 3

Qvar

Chiesi Farmaceutici S.p.A.

Preclinical

8 4

Spiriva

Boehringer Ingelheim

Preclinical

8 5

Atrovent

Boehringer Ingelheim

Preclinical

5 6

Aciphex

Akero Therapeutics

Preclinical

2 7

Tylenol

KKenvue Brands

Preclinical

1 8

CHF5993 pMDI with HFA-152a

Chiesi Farmaceutici S.p.A.

Phase 2

1 9

Aclidinium Bromide

Ozone

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Asthma

NCT07301736

Clinical

Trials by Indication[1]

Asthma1 trial

A Phase II Multinational, Multicentre, Double-blind, Randomised, Active-controlled, 3-way Cross-over Study to Evaluate the Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a Versus CHF5993 pMDI 100/6/12.5 µg HFA-134a in Subjects With Mild to Moderate Asthma

Recruiting· Chiesi Farmaceutici S.p.A. logo

Chiesi Farmaceutici S.p.A.·Phase 2·NCT07301736·780 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CHF5993 pMDI with HFA-152a. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for CHF5993 pMDI with HFA-152a. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Chiesi Farmaceutici S.p.A. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: Chiesi Farmaceutici S.p.A.

CHF5993 pMDI with HFA-152a

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Asthma1 trial

References

Drug Info

Quick Facts

Related News